文献速递慢性肾脏病

不同CKD严重程度临床试验中GFR斜率作为肾衰竭替代终点的表现差异评估

Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD.
PubMed 文献 · Clin J Am Soc Nephrol · 2023-01-19

该研究对66项CKD随机对照试验进行贝叶斯荟萃回归分析,评估GFR斜率(慢性斜率和3年总斜率)对临床终点(血清肌酐加倍、GFR<15 ml/min per 1.73 m2或肾衰竭)治疗效应的预测准确性是否受CKD严重程度影响。结果显示3年总斜率的预测表现不受疾病严重程度修饰,支持其作为不同CKD人群RCT的替代终点;而慢性斜率则存在显著修饰效应。

要点

  • 3年总斜率作为替代终点的表现不受基线GFR、基线UACR或CKD进展率修饰。
  • 慢性斜率的替代终点表现受基线GFR、基线UACR和CKD进展率显著修饰。
  • 3年总斜率在代表不同CKD人群的RCT中作为替代终点具有一致性。

核心结论

  • 3年总斜率的替代终点表现具有一致性,为其在代表不同CKD人群的RCT中作为替代终点提供了进一步证据。
  • 慢性斜率的替代终点表现受CKD严重程度修饰。

研究设计与样本

  • 对66项CKD随机对照试验进行贝叶斯荟萃回归分析。
  • 评估GFR斜率(慢性斜率和3年总斜率,以ml/min per 1.73 m2/yr的均值差表示)与临床终点(血清肌酐加倍、GFR<15 ml/min per 1.73 m2或肾衰竭,以对数风险比表示)治疗效应之间的关联。
  • 模型允许与定义疾病严重程度的变量交互,评估基线GFR(每10 ml/min per 1.73 m2)、基线UACR(每倍增mg/g)和CKD进展率(对照组慢性斜率,ml/min per 1.73 m2/yr)三个指标。
  • 当交互项95%后验可信区间排除零时定义为强修饰证据。

主要发现

  • 评估3年总斜率时,无疾病严重程度修饰证据(交互斜率95%可信区间:基线GFR [-0.05至0.03];基线UACR [-0.02至0.04];CKD进展率 [-0.07至0.02])。
  • 评估慢性斜率时,存在强修饰证据(95%可信区间:基线GFR [0.02至0.11];基线UACR [-0.11至-0.02];CKD进展率 [0.01至0.15])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The GFR slope has been evaluated as a surrogate end point for kidney failure in meta-analyses on a broad collection of randomized controlled trials (RCTs) in CKD. These analyses evaluate how accurately a treatment effect on GFR slope predicts a treatment effect on kidney failure. We sought to determine whether severity of CKD in the patient population modifies the performance of GFR slope. METHODS: We performed Bayesian meta-regression analyses on 66 CKD RCTs to evaluate associations between effects on GFR slope (the chronic slope and the total slope over 3 years, expressed as mean differences in ml/min per 1.73 m2/yr) and those of the clinical end point (doubling of serum creatinine, GFR <15 ml/min per 1.73 m2, or kidney failure, expressed as a log-hazard ratio), where models allow interaction with variables defining disease severity. We evaluated three measures (baseline GFR in 10 ml/min per 1.73 m2, baseline urine albumin-to-creatinine ratio [UACR] per doubling in mg/g, and CKD progression rate defined as the control arm chronic slope, in ml/min per 1.73 m2/yr) and defined strong evidence for modification when 95% posterior credible intervals for interaction terms excluded zero. RESULTS: There was no evidence for modification by disease severity when evaluating 3-year total slope (95% credible intervals for the interaction slope: baseline GFR [-0.05 to 0.03]; baseline UACR [-0.02 to 0.04]; CKD progression rate [-0.07 to 0.02]). There was strong evidence for modification in evaluations of chronic slope (95% credible intervals: baseline GFR [0.02 to 0.11]; baseline UACR [-0.11 to -0.02]; CKD progression rate [0.01 to 0.15]). CONCLUSIONS: These analyses indicate consistency of the performance of total slope over 3 years, which provides further evidence for its validity as a surrogate end point in RCTs representing varied CKD populations.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Collier W, Inker LA, Haaland B, et al. Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD. Clin J Am Soc Nephrol. 2023. PMID: 36754007. doi:10.2215/CJN.0000000000000050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。